D-0535-2025 Class II
FDA drug recall D-0535-2025 was initiated by Imprimis NJOF, LLC on Jul 9, 2025 and is designated Class II. Reason for recall: Sub-Potent Drug: Subpotent assay results during stability testing. Affected quantity: 6,880 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 30, 2025
- Initiation Date
- Jul 9, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 6,880 vials
Product description
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01
Reason for recall
Sub-Potent Drug: Subpotent assay results during stability testing.
Distribution pattern
Nationwide in the USA
Code information
Lot: 24DEC017, Exp. 07/12/2025.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0535-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026